RxDoctor Payments Data

Ashley Westphalen

Psychiatric/Mental Health · Omaha, NENPI 1629714449

Payments from drug & device makers

$409in general payments, 2019–2025

Across 18 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$98
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$85
  • AbbVie$60
  • Otsuka America Pharmaceutical, Inc.$39
  • Neurocrine Biosciences, Inc.$31
  • Corium, LLC$25
  • plus $70 from 4 others

What the payments were for

  • Food & beverage$409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$409 in reported general payments places this provider in the 30th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$16,029
Medicare patients
36
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$48,187
VraylarCariprazine Hcl16$38,054
AristadaAripiprazole Lauroxil13$23,064
RexultiBrexpiprazole11$16,223
Lurasidone Hcl13$4,930
Aripiprazole98$3,327
Olanzapine70$1,764
Naltrexone Hcl46$1,667
Fluphenazine Decanoate13$1,555
Divalproex Sodium ErDivalproex Sodium13$1,461
Paliperidone ErPaliperidone14$1,459
Oxcarbazepine21$1,407
Ziprasidone Hcl15$1,406
Prazosin Hcl89$1,278
Duloxetine Hcl66$1,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$19$48,18713 claims
AbbVieVraylar$60$38,05416 claims
Otsuka America Pharmaceutical, Inc.Rexulti$39$16,22311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →